AZD 9139

Drug Profile

AZD 9139

Alternative Names: AZD9139

Latest Information Update: 22 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Gastrokinetics
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 27 Jan 2005 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (unspecified route)
  • 20 Oct 2004 Preclinical trials in Gastro-oesophageal reflux in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top